Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Net Income (2016 - 2025)

Amphastar Pharmaceuticals has reported Net Income over the past 13 years, most recently at $58.4 million for Q4 2025.

  • Quarterly results put Net Income at $58.4 million for Q4 2025, up 34.67% from a year ago — trailing twelve months through Dec 2025 was $132.1 million (down 20.2% YoY), and the annual figure for FY2025 was $132.1 million, down 20.2%.
  • Net Income for Q4 2025 was $58.4 million at Amphastar Pharmaceuticals, up from $17.3 million in the prior quarter.
  • Over the last five years, Net Income for AMPH hit a ceiling of $58.4 million in Q4 2025 and a floor of -$145.2 million in Q4 2023.
  • Median Net Income over the past 5 years was $25.9 million (2023), compared with a mean of $14.4 million.
  • Biggest five-year swings in Net Income: soared 703.36% in 2021 and later tumbled 494.19% in 2022.
  • Amphastar Pharmaceuticals' Net Income stood at $23.7 million in 2021, then tumbled by 494.19% to -$93.2 million in 2022, then tumbled by 55.79% to -$145.2 million in 2023, then soared by 129.86% to $43.4 million in 2024, then soared by 34.67% to $58.4 million in 2025.
  • The last three reported values for Net Income were $58.4 million (Q4 2025), $17.3 million (Q3 2025), and $31.0 million (Q2 2025) per Business Quant data.